New models towards assessing anti-cancer therapeutics

Histology and Histopathology

Volumn 27, Issue 2, 2012, Pages 157-170

  Romero Camarero, Isabel ^a   Barajas Diego, Marcos ^a   Castellanos Martín, Andrés ^a   García Martín, Ángel ^b   Varela, Gonzalo ^c   Abad, Mar ^c   Ludeña, María Dolores ^c   Pérez Losada, Jesús ^a   Sánchez García, Isidro ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Cell Reprogramming Unit   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Cancer stem cells; Cancer treatments; Molecular image; Mouse models; Pharmacogenomics; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; METHODOLOGY; MOUSE; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MICE; NEOPLASMS; RESEARCH DESIGN;

EID: 84857716602     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Aguirre-Ghiso J.A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834-846.
2. Al-Hajj M. and Clarke M.F. (2004). Self-renewal and solid tumor stem cells. Oncogene 23, 7274-7282.
3. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J. and Clarke M.F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983-3988.
4. Al-Hajj M., Becker M.W., Wicha M., Weissman I. and Clarke M.F. (2004). Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 14, 43-47.
5. Allen T.M. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750-763.
6. Arbilly M., Pisante A., Devor M. and Darvasi A. (2006). An integrative approach for the identification of quantitative trait loci. Anim. Genet. 37 (Suppl 1), 7-9.
7. Balmain A. (2002). Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell 108, 145-152.
8. Balmain A. and Harris C.C. (2000). Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis 21, 371-377.
9. Balmain A., Gray J. and Ponder B. (2003). The genetics and genomics of cancer. Nat. Genet. 33 (Suppl), 238-244.
10. Bhatia R., Holtz M., Niu N., Gray R., Snyder D.S., Sawyers C.L., Arber D.A., Slovak M.L. and Forman S.J. (2003). Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701-4707.
11. Blasco R.B., Francoz S., Santamaría D., Cañamero M., Dubus P., Charron J., Baccarini M., and Barbacid M. (2011). c-Raf, but not BRaf, is essential for development of K-Ras oncogene-driven nonsmall cell lung carcinoma. Cancer Cell 19, 652-663.
12. Boivin G.P., Washington K., Yang K., Ward J.M., Pretlow T.P., Russell R., Besselsen D.G., Godfrey V.L., Doetschman T., Dove W.F., Pitot H.C., Halberg R.B., Itzkowitz S.H., Groden J. and Coffey R.J. (2003). Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124, 762-777.
13. Bonnet D. and Dick J.E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737.
14. Bundred N. (2005). Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptorpositive advanced breast cancer. Cancer Invest. 23, 173-181.
15. Cardiff R.D., Anver M.R., Gusterson B.A., Hennighausen L., Jensen R.A., Merino M.J., Rehm S., Russo J., Tavassoli F.A., Wakefield L.M., Ward J.M. and Green J.E. (2000). The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 19, 968-988.
16. Carmichael A., Sami A.S. and Dixon J.M. (2003). Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionising radiation. Eur. J. Surg. Oncol. 29, 475-479.
17. Castellanos A, Vicente-Dueñas C, Campos-Sánchez E, Cruz JJ, García-Criado FJ, García-Cenador MB, Lazo PA, Pérez-Losada J and Sánchez-García I. (2010). Cancer as a reprogramming-like disease: implications in tumor development and treatment. Semin. Cancer Biol. 20(2), 93-97.
18. Chimpanzee Sequencing and Analysis Consortium. (2005). Initial sequence of the chimpanzee genome and comparison with the human genome. Nature 437, 69-87.
19. Chabner B.A. and Roberts T.G. Jr (2005). Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer 5, 65-72.
20. Chang W.J., Lau L.G., Yusof N. and Mow B.M. (2005). Targeted therapy in multiple myeloma. Cancer Control 12, 91-104.
21. Chu S., Xu H., Shah N.P., Snyder D.S., Forman S.J., Sawyers C.L. and Bhatia R. (2005). Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105, 2093-2098.
22. Clarke M.F. (2005). Self-renewal and solid-tumor stem cells. Biol. Blood Marrow Transplant. 11, 14-16.
23. Cobaleda C, and Sánchez-García I. (2009). B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin. Bioessays 31, 600-609.
24. Cobaleda C., Gutierrez-Cianca N., Perez-Losada J., Flores T., Garcia-Sanz R., Gonzalez M. and Sanchez-Garcia I. (2000). A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 95, 1007-1013.
25. Delozier T. (2005). Hormone therapy in breast cancer: the end of tamoxifen? Bull Cancer 92, 142-150.
26. Desai K.V., Xiao N., Wang W., Gangi L., Greene J., Powell J.I., Dickson R., Furth P., Hunter K., Kucherlapati R., Simon R., Liu E.T. and Green J.E. (2002). Initiating oncogenic event determines geneexpression patterns of human breast cancer models. Proc. Natl. Acad. Sci. USA 99, 6967-6972.
27. DiPetrillo K., Wang X., Stylianou I.M. and Paigen B. (2005). Bioinformatics toolbox for narrowing rodent quantitative trait loci. Trends Genet. 21, 683-692.
28. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S. and Sawyers C.L. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037.
29. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., Radich J., Anderson G. and Hartwell L. (2003). The case for early detection. Nat. Rev. Cancer 3, 243-252.
30. Ewart-Toland A., Briassouli P., de Koning J.P., Mao J.H., Yuan J., Chan F., MacCarthy-Morrogh L., Ponder B.A., Nagase H., Burn J., Ball S., Almeida M., Linardopoulos S., and Balmain A. (2003). Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat. Genet. 34, 403-412.
31. Ewart-Toland A., Dai Q., Gao Y.T., Nagase H., Dunlop M.G., Farrington S.M., Barnetson R.A., Anton-Culver H., Peel D., Ziogas A., Lin D., Miao X., Sun T., Ostrander E.A., Stanford J.L., Langlois M., Chan J.M., Yuan J., Harris C.C., Bowman E.D., Clayman G.L., Lippman S.M., Lee J.J., Zheng W. and Balmain A. (2005). Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 26, 1368-1373.
32. Frazer K.A., Eskin E., Kang H.M., Bogue M.A., Hinds D.A., Beilharz E.J., Gupta R.V., Montgomery J., Morenzoni M.M., Nilsen G.B., Pethiyagoda C.L., Stuve L.L., Johnson F.M., Daly M.J., Wade C.M. and Cox D.R. (2007). A sequence-based variation map of 8.27 million SNPs in inbred mouse strains. Nature 448, 1050-1053.
33. Goldstein D.B., Tate S.K. and Sisodiya S.M. (2003). Pharmacogenetics goes genomic. Nat. Rev. Genet. 4, 937-947.
34. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L. and Holyoake T.L. (2002). Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325.
35. Greaves M. (1996). Is telomerase activity in cancer due to selection of stem cells and differentiation arrest? Trends Genet. 12, 127-128.
36. Green J.E. and Hudson T. (2005). The promise of genetically engineered mice for cancer prevention studies. Nat. Rev. Cancer 5, 184-198.
37. Hanahan D. and Weinberg R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
38. Hartwell L. (1992). Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71, 543-546.
39. Herranz M and Sánchez-García I. (2007). Medical chemistry to spy cancer stem cells from outside the body. Mini Rev. Med. Chem. 7, 781-791.
40. Hitzemann R., Malmanger B., Cooper S., Coulombe S., Reed C., Demarest K., Koyner J., Cipp L., Flint J., Talbot C., Rademacher B., Buck K. and McCaughran J. Jr (2002). Multiple cross mapping (MCM) markedly improves the localization of a QTL for ethanolinduced activation. Genes Brain Behav. 1, 214-222.
41. Hunter K.W. and Crawford N.P. (2008). The future of mouse QTL mapping to diagnose disease in mice in the age of whole-genome association studies. Annu. Rev. Genet. 42, 131-141.
42. Hunter K., Welch D.R. and Liu E.T. (2003). Genetic background is an important determinant of metastatic potential. Nat. Genet. 34, 23-24; author reply 25.
43. Jackson A.L. and Loeb L.A. (1998). The mutation rate and cancer. Genetics 148, 1483-1490.
44. Jansen R.C. and Nap J.P. (2001). Genetical genomics: the added value from segregation. Trends Genet. 17, 388-391.
45. Joensuu H., Ejlertsen B., Lonning P.E. and Rutqvist L.E. (2005). Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncol. 44, 23-31.
46. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., Kalyandrug S., Christian M., Arbuck S., Hollingshead M. and Sausville E.A. (2001). Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431.
47. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., Devon K., Dewar K., Doyle M., FitzHugh W., Funke R., Gage D., Harris K., Heaford A., Howland J., Kann L., Lehoczky J., LeVine R., McEwan P., McKernan K., Meldrim J., Mesirov J.P., Miranda C., Morris W., Naylor J., Raymond C., Rosetti M., Santos R., Sheridan A., Sougnez C., Stange-Thomann N., Stojanovic N., Subramanian A., Wyman D., Rogers J., Sulston J., Ainscough R., Beck S., Bentley D., Burton J., Clee C., Carter N., Coulson A., Deadman R., Deloukas P., Dunham A., Dunham I., Durbin R., French L., Grafham D., Gregory S., Hubbard T., Humphray S., Hunt A., Jones M., Lloyd C., McMurray A., Matthews L., Mercer S., Milne S., Mullikin J.C., Mungall A., Plumb R., Ross M., Shownkeen R., Sims S., Waterston R.H., Wilson R.K., Hillier L.W., McPherson J.D., Marra M.A., Mardis E.R., Fulton L.A., Chinwalla A.T., Pepin K.H., Gish W.R., Chissoe S.L., Wendl M.C., Delehaunty K.D., Miner T.L., Delehaunty A., Kramer J.B., Cook L.L., Fulton R.S., Johnson D.L., Minx P.J., Clifton S.W., Hawkins T., Branscomb E., Predki P., Richardson P., Wenning S., Slezak T., Doggett N., Cheng J.F., Olsen A., Lucas S., Elkin C., Uberbacher E., Frazier M., Gibbs R.A., Muzny D.M., Scherer S.E., Bouck J.B., Sodergren E.J., Worley K.C., Rives C.M., Gorrell J.H., Metzker M.L., Naylor S.L., Kucherlapati R.S., Nelson D.L., Weinstock G.M., Sakaki Y., Fujiyama A., Hattori M., Yada T., Toyoda A., Itoh T., Kawagoe C., Watanabe H., Totoki Y., Taylor T., Weissenbach J., Heilig R., Saurin W., Artiguenave F., Brottier P., Bruls T., Pelletier E., Robert C., Wincker P., Smith D.R., Doucette-Stamm L., Rubenfield M., Weinstock K., Lee H.M., Dubois J., Rosenthal A., Platzer M., Nyakatura G., Taudien S., Rump A., Yang H., Yu J., Wang J., Huang G., Gu J., Hood L., Rowen L., Madan A., Qin S., Davis R.W., Federspiel N.A., Abola A.P., Proctor M.J., Myers R.M., Schmutz J., Dickson M., Grimwood J., Cox D.R., Olson M.V., Kaul R., Raymond C., Shimizu N., Kawasaki K., Minoshima S., Evans G.A., Athanasiou M., Schultz R., Roe B.A., Chen F., Pan H., Ramser J., Lehrach H., Reinhardt R., McCombie W.R., de la Bastide M., Dedhia N., Blöcker H., Hornischer K., Nordsiek G., Agarwala R., Aravind L., Bailey J.A., Bateman A., Batzoglou S., Birney E., Bork P., Brown D.G., Burge C.B., Cerutti L., Chen H.C., Church D., Clamp M., Copley R.R., Doerks T., Eddy S.R., Eichler E.E., Furey T.S., Galagan J., Gilbert J.G., Harmon C., Hayashizaki Y., Haussler D., Hermjakob H., Hokamp K., Jang W., Johnson L.S., Jones T.A., Kasif S., Kaspryzk A., Kennedy S., Kent W.J., Kitts P., Koonin E.V., Korf I., Kulp D., Lancet D., Lowe T.M., McLysaght A., Mikkelsen T., Moran J.V., Mulder N., Pollara V.J., Ponting C.P., Schuler G., Schultz J., Slater G., Smit A.F., Stupka E., Szustakowski J., Thierry-Mieg D., Thierry-Mieg J., Wagner L., Wallis J., Wheeler R., Williams A., Wolf Y.I., Wolfe K.H., Yang S.P., Yeh R.F., Collins F., Guyer M.S., Peterson J., Felsenfeld A., Wetterstrand K.A., Patrinos A., Morgan M.J., de Jong P., Catanese J.J., Osoegawa K., Shizuya H., Choi S., Chen Y.J.; International Human Genome Sequencing Consortium. (2001). Initial sequencing and analysis of the human genome. Nature 409, 860-921.
48. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A. and Dick J.E. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648.
49. Lengauer C., Kinzler K.W. and Vogelstein B. (1998). Genetic instabilities in human cancers. Nature 396, 643-649.
50. Liggett S.B. (2004). Genetically modified mouse models for pharmacogenomic research. Nat. Rev. Genet. 5, 657-663.
51. Lindblad-Toh K., Wade C.M., Mikkelsen T.S., Karlsson E.K., Jaffe D.B., Kamal M., Clamp M., Chang J.L., Kulbokas E.J. 3rd, Zody M.C., Mauceli E., Xie X., Breen M., Wayne R.K., Ostrander E.A., Ponting C.P., Galibert F., Smith D.R., DeJong P.J., Kirkness E., Alvarez P., Biagi T., Brockman W., Butler J., Chin C.W., Cook A., Cuff J., Daly M.J., DeCaprio D., Gnerre S., Grabherr M., Kellis M., Kleber M., Bardeleben C., Goodstadt L., Heger A., Hitte C., Kim L., Koepfli K.P., Parker H.G., Pollinger J.P., Searle S.M., Sutter N.B., Thomas R., Webber C., Baldwin J., Abebe A., Abouelleil A., Aftuck L., Ait-Zahra M., Aldredge T., Allen N., An P., Anderson S., Antoine C., Arachchi H., Aslam A., Ayotte L., Bachantsang P., Barry A., Bayul T., Benamara M., Berlin A., Bessette D., Blitshteyn B., Bloom T., Blye J., Boguslavskiy L., Bonnet C., Boukhgalter B., Brown A., Cahill P., Calixte N., Camarata J., Cheshatsang Y., Chu J., Citroen M., Collymore A., Cooke P., Dawoe T., Daza R., Decktor K., DeGray S., Dhargay N., Dooley K., Dooley K., Dorje P., Dorjee K., Dorris L., Duffey N., Dupes A., Egbiremolen O., Elong R., Falk J., Farina A., Faro S., Ferguson D., Ferreira P., Fisher S., FitzGerald M., Foley K., Foley C., Franke A., Friedrich D., Gage D., Garber M., Gearin G., Giannoukos G., Goode T., Goyette A., Graham J., Grandbois E., Gyaltsen K., Hafez N., Hagopian D., Hagos B., Hall J., Healy C., Hegarty R., Honan T., Horn A., Houde N., Hughes L., Hunnicutt L., Husby M., Jester B., Jones C., Kamat A., Kanga B., Kells C., Khazanovich D., Kieu A.C., Kisner P., Kumar M., Lance K., Landers T., Lara M., Lee W., Leger J.P., Lennon N., Leuper L., LeVine S., Liu J., Liu X., Lokyitsang Y., Lokyitsang T., Lui A., Macdonald J., Major J., Marabella R., Maru K., Matthews C., McDonough S., Mehta T., Meldrim J., Melnikov A., Meneus L., Mihalev A., Mihova T., Miller K., Mittelman R., Mlenga V., Mulrain L., Munson G., Navidi A., Naylor J., Nguyen T., Nguyen N., Nguyen C., Nguyen T., Nicol R., Norbu N., Norbu C., Novod N., Nyima T., Olandt P., O'Neill B., O'Neill K., Osman S., Oyono L., Patti C., Perrin D., Phunkhang P., Pierre F., Priest M., Rachupka A., Raghuraman S., Rameau R., Ray V., Raymond C., Rege F., Rise C., Rogers J., Rogov P., Sahalie J., Settipalli S., Sharpe T., Shea T., Sheehan M., Sherpa N., Shi J., Shih D., Sloan J., Smith C., Sparrow T., Stalker J., Stange-Thomann N., Stavropoulos S., Stone C., Stone S., Sykes S., Tchuinga P., Tenzing P., Tesfaye S., Thoulutsang D., Thoulutsang Y., Topham K., Topping I., Tsamla T., Vassiliev H., Venkataraman V., Vo A., Wangchuk T., Wangdi T., Weiand M., Wilkinson J., Wilson A., Yadav S., Yang S., Yang X., Young G., Yu Q., Zainoun J., Zembek L., Zimmer A. and Lander E.S. (2005). Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438, 803-819.
52. Livingston J.N. (1999). Genetically engineered mice in drug development. J. Intern. Med. 245, 627-635.
53. Loeb L.A. (1991). Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51, 3075-3079.
54. Mackay T.F. (2001). Quantitative trait loci in Drosophila. Nat. Rev. Genet. 2, 11-20.
55. Maggi A. and Ciana P. (2005). Reporter mice and drug discovery and development. Nat. Rev. Drug Discov. 4, 249-255.
56. Massoud T.F. and Gambhir S.S. (2003). Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 17, 545-580.
57. Matsui W., Huff C.A., Wang Q., Malehorn M.T., Barber J., Tanhehco Y., Smith B.D., Civin C.I. and Jones R.J. (2004). Characterization of clonogenic multiple myeloma cells. Blood 103, 2332-2336.
58. Mauro M.J. and Druker B.J. (2001a). STI571: a gene product-targeted therapy for leukemia. Curr. Oncol. Rep. 3, 223-227.
59. Mauro M.J. and Druker B.J. (2001b). STI571: targeting BCR-ABL as therapy for CML. Oncologist 6, 233-238.
60. Pal S.K. and Pegram M. (2005). Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs 16, 483-494.
61. Pérez-Caro M., Pérez-Mancera P.A., Voces F. and Sánchez García I. (2005). Of man in mouse: modelling human cancer genotypephenotype correlations in mice. Current Genomics 6, 81-88.
62. Pérez-Caro M, Cobaleda C, González-Herrero I, Vicente-Dueñas C, Bermejo-Rodríguez C, Sánchez-Beato M, Orfao A, Pintado B, Flores T, Sánchez-Martín M, Jiménez R, Piris MA and Sánchez-García I. (2009). Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J. 28, 8-20.
63. Peterson J.K. and Houghton P.J. (2004). Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 40, 837-844.
64. Quigley D. and Balmain A. (2009). Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat. Rev. Genet 10, 651-657.
65. Quigley D.A., To M.D., Perez-Losada J., Pelorosso F.G., Mao J.H., Nagase H., Ginzinger D.G. and Balmain A. (2009). Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature 458, 505-508.
66. Reya T., Morrison S.J., Clarke M.F. and Weissman I.L. (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
67. Rudin M. and Weissleder R. (2003). Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2, 123-131.
68. Ruiz i Altaba A., Sanchez P. and Dahmane N. (2002). Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat. Rev. Cancer 2, 361-372.
69. Sanchez I., San Miguel J.F., Corral J., Martin C., Perez R., Gonzalez M., Canizo M.C., Orfao A. and Gonzalez-Sarmiento R. (1995). Gene rearrangement in acute non-lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells. Br. J. Haematol 89, 104-109.
70. Sánchez-García I. (2009). The crossroads of oncogenesis and metastasis. N. Engl. J. Med. 360, 297-299.
71. Sánchez-García I. (2010). Getting to the stem of cancer. Semin. Cancer Biol. 20, 63-64.
72. Sanchez-Garcia, I., San Miguel J.F. and Gonzalez-Sarmiento R. (1999). Immunoglobulin lambda chain gene rearrangement in a case of acute nonlymphoblastic leukemia. Leukemia 13, 485-487.
73. Sánchez-García I., Vicente-Dueñas C. and Cobaleda C. (2007). The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice? Bioessays 29, 1269-1280.
74. Sawyers C. (2004). Targeted cancer therapy. Nature 432, 294-297.
75. Setoguchi T., Taga T. and Kondo T. (2004). Cancer stem cells persist in many cancer cell lines. Cell Cycle 3, 414-415.
76. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J. and Sawyers C.L. (2002). Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125.
77. Shet A.S., Jahagirdar B.N. and Verfaillie C.M. (2002). Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 16, 1402-1411.
78. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J. and Dirks P.B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828.
79. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J. and Norton L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792.
80. Smigal C., Jemal A., Ward E., Cokkinides V., Smith R., Howe H.L. and Thun M. (2006). Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J. Clin. 56, 168-183.
81. Spangrude G.J., Heimfeld S. and Weissman I.L. (1988). Purification and characterization of mouse hematopoietic stem cells. Science 241, 58-62.
82. Sullivan D.C. and Kelloff G. (2005). Seeing into cells. The promise of in vivo molecular imaging in oncology. EMBO Rep. 6, 292-296.
83. To M.D., Perez-Losada J., Mao J.H., Hsu J., Jacks T. and Balmain A. (2006). A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat. Genet. 38, 926-930.
84. Venook A. (2005). Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 10, 250-261.
85. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I, Charlab R., Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K., Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov GV., Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D., McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M., Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C., Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigó R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B., Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J., Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E., Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A. and Zhu X. (2001). The sequence of the human genome. Science 291, 1304-1351.
86. Vicente-Dueñas C., Pérez-Caro M., Abollo-Jiménez F., Cobaleda C. and Sánchez-García I. (2009). Stem-cell driven cancer: hands-off regulation of cancer development. Cell Cycle 8, 1314-1318.
87. Vicente-Dueñas C., Cobaleda C., Pérez-Losada J. and Sánchez-García I. (2010) The evolution of cancer modeling: the shadow of stem cells. Dis. Model. Mech. 3, 149-55.
88. Waterston R.H., Lindblad-Toh K., Birney E., Rogers J., Abril J.F., Agarwal P., Agarwala R., Ainscough R., Alexandersson M., An P., Antonarakis S.E., Attwood J., Baertsch R., Bailey J., Barlow K., Beck S., Berry E., Birren B., Bloom T., Bork P., Botcherby M., Bray N., Brent M.R., Brown D.G., Brown S.D., Bult C., Burton J., Butler J., Campbell R.D., Carninci P., Cawley S., Chiaromonte F., Chinwalla A.T., Church D.M., Clamp M., Clee C., Collins F.S., Cook L.L., Copley R.R., Coulson A., Couronne O., Cuff J., Curwen V., Cutts T., Daly M., David R., Davies J., Delehaunty K.D., Deri J., Dermitzakis E.T., Dewey C., Dickens N.J., Diekhans M., Dodge S., Dubchak I., Dunn D.M., Eddy S.R., Elnitski L., Emes R.D., Eswara P., Eyras E., Felsenfeld A., Fewell G.A., Flicek P., Foley K., Frankel W.N., Fulton L.A., Fulton R.S., Furey T.S., Gage D., Gibbs R.A., Glusman G., Gnerre S., Goldman N., Goodstadt L., Grafham D., Graves T.A., Green E.D., Gregory S., Guigó R., Guyer M., Hardison R.C., Haussler D., Hayashizaki Y., Hillier L.W., Hinrichs A., Hlavina W., Holzer T., Hsu F., Hua A., Hubbard T., Hunt A., Jackson I., Jaffe D.B., Johnson L.S., Jones M., Jones T.A., Joy A., Kamal M., Karlsson E.K., Karolchik D., Kasprzyk A., Kawai J., Keibler E., Kells C., Kent W.J., Kirby A., Kolbe D.L., Korf I., Kucherlapati R.S., Kulbokas E.J., Kulp D., Landers T., Leger J.P., Leonard S., Letunic I., Levine R., Li J., Li M., Lloyd C., Lucas S., Ma B., Maglott D.R., Mardis E.R., Matthews L., Mauceli E., Mayer J.H., McCarthy M., McCombie W.R., McLaren S., McLay K., McPherson J.D., Meldrim J., Meredith B., Mesirov J.P., Miller W., Miner T.L., Mongin E., Montgomery K.T., Morgan M., Mott R., Mullikin J.C., Muzny D.M., Nash W.E., Nelson J.O., Nhan M.N., Nicol R., Ning Z., Nusbaum C., O'Connor M.J., Okazaki Y., Oliver K., Overton-Larty E., Pachter L., Parra G., Pepin K.H., Peterson J., Pevzner P., Plumb R., Pohl C.S., Poliakov A., Ponce T.C., Ponting C.P., Potter S., Quail M., Reymond A., Roe B.A., Roskin K.M., Rubin E.M., Rust A.G., Santos R., Sapojnikov V., Schultz B., Schultz J., Schwartz M.S., Schwartz S., Scott C., Seaman S., Searle S., Sharpe T., Sheridan A., Shownkeen R., Sims S., Singer J.B., Slater G., Smit A., Smith D.R., Spencer B., Stabenau A., Stange-Thomann N., Sugnet C., Suyama M., Tesler G., Thompson J., Torrents D., Trevaskis E., Tromp J., Ucla C., Ureta-Vidal A., Vinson J.P., Von Niederhausern A.C., Wade C.M., Wall M., Weber R.J., Weiss R.B., Wendl M.C., West A.P., Wetterstrand K., Wheeler R., Whelan S., Wierzbowski J., Willey D., Williams S., Wilson R.K., Winter E., Worley K.C., Wyman D., Yang S., Yang S.P., Zdobnov E.M., Zody M.C. and Lander E.S. (2002). Initial sequencing and comparative analysis of the mouse genome. Nature 420, 520-562.
89. Weaver Z., Montagna C., Xu X., Howard T., Gadina M., Brodie S.G., Deng C.X. and Ried T. (2002). Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 21, 5097-5107.
90. Weinshilboum R. (2003). Inheritance and drug response. N. Engl. J. Med. 348, 529-537.
91. Winter S.F. and Hunter K.W. (2008). Mouse modifier genes in mammary tumorigenesis and metastasis. J. Mammary Gland Biol. Neoplasia 13, 337-342.